Cyclometalated Iridium Complexes Research Articles

Application of Mono and Trinuclear Cyclometalated Iridium (III) Complexes in Differential Bacterial Imaging and Antimicrobial Photodynamic Therapy.

The application of transition metal complexes for antimicrobial photodynamic therapy (PDT) has emerged as an attractive alternative in mitigating a broad range of bacterial pathogens, including multidrug-resistant pathogens. In view of their photostability, long excited-state lifetimes, and tunable emission properties, transition metal complexes also contribute as bioimaging agents. In the present work, we designed mono and trinuclear cyclometalated iridium (III) complexes to explore their imaging application and antibacterial potential. For this, we used Methicillin-resistant S. aureus (MRSA), the most prevalent of community-associated (CA) multidrug-resistant (MDR) bacteria (CA MDR) and Lactococcus lactis (L. lactis) as Gram-positive while Campylobacter jejuni (C. jejuni) and E. coli as Gram-negative bacteria. In addition to differential bioimaging of these bacteria, we assessed the antibacterial effects of both mono and trinuclear Ir(III) complexes under exposure to 427 nm LED light. The data presented herein strongly suggest better efficacy of trinuclear Ir(III) complex over the mononuclear complex in imparting photoinduced cell death of MRSA. Based on the safety profile of these complexes, we propose that trinuclear cyclometalated iridium(III) complex holds great promise for selective recognition and targeting MDR bacteria with minimal off-target effect.

Electrogenerated Chemiluminescence Biosensor for Quantization of Matrix Metalloproteinase-3 in Serum via Target-Induced Cleavage of Oligopeptide

A highly sensitive and selective electrogenerated chemiluminescence (ECL) biosensor was developed for the determination of matrix metalloproteinase 3 (MMP-3) in serum via the target-induced cleavage of an oligopeptide. One ECL probe (named as Ir-peptide) was synthesized by covalently linking a new cyclometalated iridium(III) complex ([(3-pba)2Ir(bpy-COOH)](PF6)) (3-pba = 3-(2-pyridyl) benzaldehyde, bpy-COOH = 4′-methyl-2,2′-bipyridine-4-carboxylic acid) with an oligopeptide (CGVPLSLTMGKGGK). An ECL biosensor was fabricated by firstly casting Nafion and gold nanoparticles (AuNPs) on a glassy carbon electrode and then self-assembling both of the ECL probes, 6-mercapto-1-hexanol and zwitterionic peptide, on the electrode surface, from which the AuNPs could be used to amplify the ECL signal and Ir-peptide could serve as an ECL probe to detect the MMP-3. Thanks to the MMP-3-induced cleavage of the oligopeptide contributing to the decrease in ECL intensity and the amplification of the ECL signal using AuNPs, the ECL biosensor could selectively and sensitively quantify MMP-3 in the concentration range of 10–150 ng·mL−1 and with both a limit of quantification (26.7 ng·mL−1) and a limit of detection (8.0 ng·mL−1) via one-step recognition. In addition, the developed ECL biosensor showed good performance in the quantization of MMP-3 in serum samples, with a recovery of 92.6% ± 2.8%–105.6% ± 5.0%. An increased level of MMP-3 was found in the serum of rheumatoid arthritis patients compared with that of healthy people. This work provides a sensitive and selective biosensing method for the detection of MMP-3 in human serum, which is promising in the identification of patients with rheumatoid arthritis.

Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response.

To develop a potential theranostic metal agent to reverse the resistance of cancer cells to cisplatin and effectively inhibit tumor growth and metastasis, we proposed to design a cyclometalated iridium (Ir) complex based on the properties of the tumor environment (TME). To the end, we designed and synthesized a series of Ir(III) 2-hydroxy-1-naphthaldehyde thiosemicarbazone complexes by modifying the hydrogen atom(s) of the N-3 position of 2-hydroxy-1-naphthaldehyde thiosemicarbazone compounds and the structure of cyclometalated Ir(III) dimers and then investigated their structure-activity and structure-fluorescence relationships to obtain an Ir(III) complex (Ir5) with remarkable fluorescence and cytotoxicity to cancer cells. Ir5 not only possesses mitochondria-targeted properties but also overcomes cisplatin resistance and effectively inhibits tumor growth and metastasis in vivo. Besides, we confirmed the anticancer mechanisms of Ir5 acting on different components in the TME: directly killing liver cancer cells by inducing necroptosis and activating the necroptosis-related immune response.

An Ir (III) complex with multiphoton absorption in the near-infrared region as a probe for mtDNA-specific recognition and mitochondrial imaging

The multiphoton absorbing (MPA) materials have been extensively investigated due to their crucial merits of long wavelength excitation and short wavelength emission, of which the organometallic complexes are the most promising but still challenging candidates for developing efficient MPA materials. Herein, a novel cyclometallated iridium complex (abbreviated as SQ) is reported as a multiphoton absorption phosphorescent probe, which is constructed by coordinating the central metal Ir with diethoxyphenyl terpyridine, phenyl pyridine and SCN ligands. The single crystal of SQ exhibits a twisted octahedral structure that can avoid phosphorescence quenching caused by π-π stacking, and the push-pull electron effect of the ligand endows SQ with excellent nonlinear optical (NLO) properties under near-infrared excitation. As a result, two-photon imaging with deep tissue penetration depths is realized at the excitation wavelength of 750 nm. Meanwhile, the planar conjugated structure of diethoxyphenyl terpyridine facilitates the insertion of SQ into base pairs of mitochondrial DNA (mtDNA), thus limiting the intramolecular rotation. Consequently, the emission intensity of the SQ solution enhanced approximately 10-fold after mtDNA was introduced, which led to mtDNA-specific recognition. Our work proves a new way of designing a phosphorescence probe that can specifically identify mtDNA, thus realizing dynamic monitoring of mitochondria.

Yellow Phosphorescent Electrogenerated Chemiluminescence Cell Based on a Cyclometalated Iridium Complex with a Redox Mediator

Yellow Phosphorescent Electrogenerated Chemiluminescence Cell Based on a Cyclometalated Iridium Complex with a Redox Mediator

Phototoxicity of cyclometallated Ir(III) complexes bearing a thio-bis-benzimidazole ligand, and its monodentate analogue, as potential PDT photosensitisers in cancer cell killing

Two novel cyclometallated iridium(III) complexes have been prepared with one bidentate or two monodentate imidazole-based ligands, 1 and 2, respectively. The complexes showed intense emission with long lifetimes of the excited state. Femtosecond transient absorption experiments established the nature of the lowest excited state as 3IL state. Singlet oxygen generation with good yields (40% for 1 and 82% for 2) was established by detecting 1O2 directly, through its emission at 1270 nm. Photostability studies were also performed to assess the viability of the complexes as photosensitizers (PS) for photodynamic therapy (PDT). Complex 1 was selected as a good candidate to investigate light-activated killing of cells, whilst complex 2 was found to be toxic in the dark and unstable under light. Complex 1 demonstrated high phototoxicity indexes (PI) in the visible region, PI > 250 after irradiation at 405 nm and PI > 150 at 455 nm, in EJ bladder cancer cells.Graphical abstract

Recent Advances in Organometallic NIR Iridium(III) Complexes for Detection and Therapy.

Iridium(III) complexes are emerging as a promising tool in the area of detection and therapy due to their prominent photophysical properties, including higher photostability, tunable phosphorescence emission, long-lasting phosphorescence, and high quantum yields. In recent years, much effort has been devoted to develop novel near-infrared (NIR) iridium(III) complexes to improve signal-to-noise ratio and enhance tissue penetration. In this review, we summarize different classes of organometallic NIR iridium(III) complexes for detection and therapy, including cyclometalated ligand-enabled NIR iridium(III) complexes and NIR-dye-conjugated iridium(III) complexes. Moreover, the prospects and challenges for organometallic NIR iridium(III) complexes for targeted detection and therapy are discussed.

Mitochondria-targeted neutral and cationic iridium(III) anticancer complexes chelating simple hybrid sp2-N/sp3-N donor ligands.

Most platinum group-based cyclometalated neutral and cationic anticancer complexes with the general formula [(C^N)2Ir(XY)]0/+ (neutral complex: XY = bidentate anionic ligand; cationic complex: XY = bidentate neutral ligand) are notable owing to their intrinsic luminescence properties, good cell permeability, interaction with some biomolecular targets and unique mechanisms of action (MoAs). We herein synthesized a series of neutral and cationic amine-imine cyclometalated iridium(III) complexes using Schiff base ligands with sp2-N/sp3-N N^NH2 chelating donors. The cyclometalated iridium(III) complexes were identified by various techniques. They were stable in aqueous media, displayed moderate fluorescence and exhibited affinity toward bovine serum albumin (BSA). The complexes demonstrated promising cytotoxicity against lung cancer A549 cells, cisplatin-resistant lung cancer A549/DDP cells, cervical carcinoma HeLa cells and human liver carcinoma HepG2 cells, with IC50 values ranging from 9.98 to 19.63 μM. Unfortunately, these complexes had a low selectivity (selectivity index: 1.62-1.98) towards A549 cells and BEAS-2B normal cells. The charge pattern of the metal center (neutral or cationic) and ligand substituents showed little influence on the cytotoxicity and selectivity of these complexes. The study revealed that these complexes could target mitochondria, cause depolarization of the mitochondrial membrane, and trigger the production of intracellular ROS. Additionally, the complexes were observed to induce late apoptosis and perturb the cell cycle in the G2/M or S phase in A549 cells. Based on these results, it appears that the anticancer efficacy of these complexes was predominantly attributed to the redox mechanism.

AIE-active cyclometalated iridium(iii) complexes for highly efficient picric acid detection in aqueous media

Three Ir(iii) complex-based AIEgens have been developed to detect picric acid efficiently in aqueous solution. The bright emission of these complexes in the aggregated and crystalline states is supported by crystal structure and triplet state TDDFT study.

Construction of photofunctional peptide conjugates through selective modification of N-terminal cysteine with cyclometallated iridium(III) 2-formylphenylboronic acid complexes for organelle-specific imaging, enzyme activity sensing and photodynamic therapy.

Luminescent cyclometallated iridium(III) complexes bearing a 2-formylphenylboronic acid moiety were designed; one of the complexes was utilised to modify peptides containing an N-terminal cysteine to afford luminescent conjugates with selective organelle-targeting or furin-responsive properties.

Synthetic ease and exceptional in vivo performance of pyrazole-based cyclometallated iridium complexes

Novel cyclometallated IrIII complexes, exhibiting dual functionality as potent anticancer agents and photosensitisers, with selective efficacy against specific cancer cell lines.

Impacts of ancillary ligand coordination modes on red-emitting cyclometalated iridium complexes

Red-phosphorescent bis-cyclometalated iridium compounds with salicylaldimine, 2-picolinamide, and related ancillary ligand classes are described; the 2-picolinamide analogues exhibit multiple binding modes that influence photophysical properties.

Photoluminescent and electrochemiluminescent detection of homocysteine based on bifunctional cyclometalated iridium(III) complex

A photoluminescent (PL) and electrochemiluminescent (ECL) chemodosimeter for homocysteine (Hcy) determination was developed based on a bifunctional cyclometalated iridium(III) complex (pba)2Ir(dcbpy). (pba)2Ir(dcbpy) was prepared by using 4′-(2-pyridyl)-benzaldehyde (pba) as main ligand and 2,2′-bipyridyl-4,4′-dicarboxylic acid (dcbpy) as ancillary ligand. The existence of aldehyde group on the main ligand and dicarboxylic acid groups on the ancillary ligand endows (pba)2Ir(dcbpy) good water solubility. Importantly, the aldehyde group on the main ligand also furnishes the chemodosimetric active site, which could react with Hcy highly in neutral buffer solution based on a unique cyclization reaction with aminoalkylthiol group to produce a binding adduct, enhancing both PL and ECL signal. The photophysical and ECL properties of (pba)2Ir(dcbpy) in the absence and presence of Hcy were investigated and the response mechanism of the luminescence enhancement was confirmed by mass spectrum. Both PL and ECL measurements exhibited good linear relationships to the Hcy with the detection of limit at micro-molar level. More significantly, (pba)2Ir(dcbpy) possessed a relatively high discriminating ability to differentiate Hcy from structurally related molecule (cysteine) under neutral buffer conditions. The PL and ECL chemodosimeter based on cyclometalated iridium(III) complex with specific active site is universal to the analysis of other targets, thus opening a new avenue for the application of cyclometalated iridium(III) complex in PL and ECL field.

Trifluoromethyl substituted cationic cyclometallated iridium(III) complexes: Photophysical properties and theoretical studies

Three new trifluoromethyl substituted (–CF3) cationic iridium(III) complexes 1–3, with 3,5-dimethyl-1-(3-(trifluoromethyl)phenyl)-1H-pyrazole (DTPP) as the cyclometallated ligand, namely, [Ir(DTPP)2bpy](PF6) (1, bpy = 2, 2′–bipyridine), [Ir(DTPP)2phen](PF6) (2, phen = 1,10-phenanthroline) and [Ir(DTPP)2pphen](PF6) (3, pphen = pyrazino[2,3-f][1,10]phenanthroline) have been rationally designed and synthesized in good yields (60–77%). The photophysical, electrochemical, and electroluminescent properties were fully characterized. Complexes 1–3 show bright blue to yellow emission in the both solution and neat film states with maximum emission wavelength in the range of 484–560 nm. Photoluminescence quantum yields (PLQYs) are very high ranging from 62% to 72% in the solution state with microsecond excited-state lifetimes (0.39–0.77 μs). More detailed photophysical and theortical calculation studies reveal that introduction of –CF3 substituent onto the cyclometallated ligand can induce a blue-shift emission compared with conventional fluorinated phenylpyridine or phenylpyrazole complexes, which can be contributed to the decline in HOMO energy level of complexes. Single-crystal structure analysis of complex 3 shows a distorted octahedral geometry with strong intermolecular π–π stacking (face-to-face) interactions between ancillary ligands in adjacent molecules, which might be responsible for the obviously red-shifted emission compared with complexes 1 and 2 in the aggregated state. In addition, electroluminescent properties of all three new complexes have been studied in the application of light-emitting electrochemical cells (LECs), which show green to yellow electroluminescence (λmax, EL = 516–540 nm).

Exploring a Mitochondria Targeting, Dinuclear Cyclometalated Iridium (III) Complex for Image-Guided Photodynamic Therapy in Triple-Negative Breast Cancer Cells.

Photodynamic therapy (PDT) has emerged as an efficient and noninvasive treatment approach utilizing laser-triggered photosensitizers for combating cancer. Within this rapidly advancing field, iridium-based photosensitizers with their dual functionality as both imaging probes and PDT agents exhibit a potential for precise and targeted therapeutic interventions. However, most reported classes of Ir(III)-based photosensitizers comprise mononuclear iridium(III), with very few examples of dinuclear systems. Exploring the full potential of iridium-based dinuclear systems for PDT applications remains a challenge. Herein, we report a dinuclear Ir(III) complex (IRDI) along with a structurally similar monomer complex (IRMO) having 2-(2,4-difluorophenyl)pyridine and 4'-methyl-2,2'-bipyridine ligands. The comparative investigation of the mononuclear and dinuclear Ir(III) complexes showed similar absorption profiles, but the dinuclear derivative IRDI exhibited a higher photoluminescence quantum yield (Φp) of 0.70 compared to that of IRMO (Φp = 0.47). Further, IRDI showed a higher singlet oxygen generation quantum yield (Φs) of 0.49 compared to IRMO (Φs = 0.28), signifying the enhanced potential of the dinuclear derivative for image-guided photodynamic therapy. In vitro assessments indicate that IRDI shows efficient cellular uptake and significant photocytotoxicity in the triple-negative breast cancer cell line MDA-MB-231. In addition, the presence of a dual positive charge on the dinuclear system facilitates the inherent mitochondria-targeting ability without the need for a specific targeting group. Subcellular singlet oxygen generation by IRDI was confirmed using Si-DMA, and light-activated cellular apoptosis via ROS-mediated PDT was verified through various live-dead assays performed in the presence and absence of the singlet oxygen scavenger NaN3. Further, the mechanism of cell death was elucidated by an annexin V-FITC/PI flow cytometric assay and by investigating the cytochrome c release from mitochondria using Western blot analysis. Thus, the dinuclear complex designed to enhance spin-orbit coupling with minimal excitonic coupling represents a promising strategy for efficient image-guided PDT using iridium complexes.

Cascading Energy Transfer for Highly Efficient Deep-Red OLED Emission with Cyclometalated [3+2+1] Iridium Complexes.

The promising cyclometalated iridium (III) complexes have been proved to possess great potential in vacuum-deposited organic light-emitting diodes (OLEDs) applications for full-color displays and white solid-state lighting sources. Herein, based on the unique bidentate ligand of dibenzo[a,c]phenazine (dbpz) group with strong conjugated effect of aromatic rings for red emission, four novel [3+2+1] coordinated iridium (III) emissive materials have been rationally designed and synthesized. The monodentate ligands of -CN and -OCN have been effectively employed to tune the deep-red emission of 628-675nm with high photoluminescence quantum yields up to 98%. Moreover, all devices displayed deep-red color coordinates ranging from (0.675, 0.325) to (0.716, 0.284), which is close to the standard-red color coordinates of (0.708, 0.292), as recommended by International Telecommunication Union Radiocommunication (ITU-R) BT.2020. The device based on nBuIr(dbpz)CN with an exciplex cohost has exhibited maximum external quantum efficiencies of 20.7% and good stability. With nBuIr(dbpz)CN as an effective sensitizer, the nBuIr(dbpz)OCN based phosphorescent OLED devices have successfully demonstrated cascading energy transfer processes, contributing to pure red emission with maximum luminance as high as 6471cd m-2. Therefore, this work has been successfully demonstrated rational molecular design strategy of [3+2+1] iridium complexes to obtain highly efficient deep-red electrophosphorescent emission.

Recent Advancement in the Synthesis of Ir-Based Complexes.

Cancer is a devastating disease with over 100 types, including lung and breast cancer. Cisplatin and metal-based drugs are limited due to their drug resistance and side effects. Iridium-based compounds have emerged as promising candidates due to their unique chemical properties and resemblance to platinum compounds. The objective of this study is to investigate the synthesis and categorization of iridium complexes, with a particular emphasis on their potential use as anticancer agents. The major focus of this research is to examine the synthesis of these complexes and their relevance to the field of cancer treatment. The negligible side effects and flexibility of cyclometalated iridium(III) complexes have garnered significant interest. Organometallic half-sandwich Ir(III) complexes have notable benefits in cancer research and treatment. The review places significant emphasis on categorizing iridium complexes according to their ligand environment, afterward considering the ligand density and coordination number. This study primarily focuses on several methods for synthesizing cyclometalated and half-sandwich Ir complexes, divided into subgroups based on ligand denticity. The coordination number of iridium complexes determines the number of ligands coordinated to the central iridium atom, which impacts their stability and reactivity. Understanding these complexes is crucial for designing compounds with desired properties and investigating their potential as anticancer agents. Cyclometalated iridium(III) complexes, which contain a meta-cycle with the E-M-C order σ bond, were synthesized in 1999. These complexes have high quantum yields, significant stock shifts, luminescence qualities, cell permeability, and strong photostability. They have been promising in biosensing, bioimaging, and phosphorescence of heavy metal complexes.

Optical modulation of Iridium(III) complexes for enhanced ROS generation: Multi-photon absorption and near-infrared photodynamic therapy insights

In this study, we harness optical modulation techniques to tailor an auxiliary ligand, thereby optimizing the photophysical behavior of cyclometalated iridium (III) complexes, Ir–B and Ir-Q, for enhanced reactive oxygen species (ROS) generation. Intriguingly, the optical properties of Ir-Q's auxiliary ligands instigate a non-radiative intersystem crossover process, yielding a superior singlet oxygen (1O2) quantum efficiency of 0.92. Further, Ir-Q's robust multi-photon absorption spectra, particularly in the Two-photon (750–800 nm) and Three-photon (1350–1600 nm) domains, open avenues for potential applications in two-photon imaging-guided photodynamic therapy targeting deep-seated tumors. This investigation underscores the pivotal role of optical structure modulation in amplifying the therapeutic potential of the iridium(III) complex, particularly in the realm of near-infrared photodynamic therapy.

Mitochondria-targeted cyclometalated iridium (III) complexes: Dual induction of A549 cells apoptosis and autophagy

In this study, we synthesized 4 cyclometalated iridium complexes using N-(1,10-phenanthrolin-5-yl)picolinamide (PPA) as the main ligand, denoted as [Ir(ppy)2PPA]PF6 (ppy = 2-phenylpyridine, Ir1), [Ir(bzq)2PPA]PF6 (bzq = benzo[h]quinoline, Ir2), [Ir(dfppy)2PPA]PF6 (dfppy = 2-(3,5-difluorophenyl)pyridine, Ir3), and [Ir(thpy)2PPA]PF6 (thpy = 2-(thiophene-2-yl)pyridine, Ir4). Compared to cisplatin and oxaliplatin, all four complexes exhibited significant anti-tumor activity. Among them, Ir2 demonstrated higher cytotoxicity against A549 cells, with an IC50 value of 1.6 ± 0.2 μM. The experimental results indicated that Ir2 primarily localized in the mitochondria, inducing a large amount of reactive oxygen species (ROS) generation, that decreased in mitochondrial membrane potential (MMP), reduced ATP production, and further impaired mitochondrial function, leading to cytochrome c release. Additionally, Ir2 caused cell cycle arrest at the S phase and induced apoptosis through the AKT-mediated signaling pathway. Further investigations revealed that Ir2 could simultaneously induce both apoptosis and autophagy in A549 cells, with the latter acting as a non-protective mechanism that promoted cell death. More importantly, Ir2 exhibited low toxicity to both normal LO2 cells in vitro and zebrafish embryos in vivo. Consequently, these newly developed Ir(III) complexes show great potential in the development of novel and low-toxicity anticancer agents.

Electrochemiluminescence bioassay with anti-fouling ability for determination of matrix metalloproteinase 9 secreted from living cells under external stimulation.

An electrochemiluminescence (ECL) bioassay with high sensitivity and anti-fouling ability was developed for determination of matrix metalloproteinase 9 (MMP-9) secreted from living cells under external stimulation. A peptide with sequence of CLGRMGLPGK and a new cyclometalated iridium(III) complex bearing carboxyl group, (pq)2Ir(dcbpy) (pq = 2-phenylquinoline, dcbpy = 2,2'-bipyridyl-4,4'-dicarboxyli acid, abbreviated as Ir) were employed as molecular recognition substrate and ECL emitter, respectively. The peptide was labelled with the Ir to form Ir-peptide as ECL probe. Ir-peptide was self-assembled onto Nafion and gold nanoparticles (AuNPs) modified glassy carbon electrode (AuNPs/Nafion/GCE) and then both of 6-mercapto-1-hexanol (MCH) and zwitterionic peptide as blocking reagents were co-assembled on Ir-peptide/AuNPs/Nafion/GCE to form an anti-fouling ECL peptide-based biosensor. MMP-9 can be quantified in the range 1.0-50ng·mL-1 with adetection limit of 0.50ng·mL-1 based on the decreased ECL intensity. Relative standard derivation was 2.3% for six fabricated anti-fouling ECL peptide-based biosensors after reaction with 50ng·mL-1 MMP-9. The anti-fouling ECL peptide-based biosensor can be used to monitor MMP-9 secreted from living cells under external stimulation. 96.0%-108.0% of recoveries were obtained in 60-diluted cell culture media. This study demonstrates that the ECL biosensor by the combination of iridium(III) complex-based sensitive ECL method and the anti-fouling interface provides a promising way for the determination of MMP-9 in biological sample, which is viable in clinical diagnosis and point-of-care test of protease.